KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker.

MLA

Kreis, Nina-Naomi, et al. “KIF2C/MCAK a Prognostic Biomarker and Its Oncogenic Potential in Malignant Progression, and Prognosis of Cancer Patients: A Systematic Review and Meta-Analysis as Biomarker.” Critical Reviews in Clinical Laboratory Sciences, vol. 61, no. 6, Sept. 2024, pp. 404–34. EBSCOhost, https://doi.org/10.1080/10408363.2024.2309933.

APA

Kreis, N.-N., Moon, H. H., Wordeman, L., Louwen, F., Solbach, C., Yuan, J., & Ritter, A. (2024). KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker. Critical Reviews in Clinical Laboratory Sciences, 61(6), 404–434. https://doi.org/10.1080/10408363.2024.2309933

Chicago

Kreis, Nina-Naomi, Ha Hyung Moon, Linda Wordeman, Frank Louwen, Christine Solbach, Juping Yuan, and Andreas Ritter. 2024. “KIF2C/MCAK a Prognostic Biomarker and Its Oncogenic Potential in Malignant Progression, and Prognosis of Cancer Patients: A Systematic Review and Meta-Analysis as Biomarker.” Critical Reviews in Clinical Laboratory Sciences 61 (6): 404–34. doi:10.1080/10408363.2024.2309933.